LYP-IN-4

LYP-IN-4

• UNSPSC Description: LYP-IN-4 (compound D14) is a reversible and selective inhibitor of lymphotyrosine phosphatase (LYP) (Ki=1.34 μM, IC50=3.52μM). LYP-IN-4 inhibits LYP to regulate TCR signaling, up-regulates PD-1/PD-L1 expression, and enhance anti-tumor immunity. LYP-IN-4 activates T cells and inhibits M2 macrophage polarization, inhibits tumor growth in MC38 isogenic mouse models.
• Target Antigen: Phosphatase
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/lyp-in-4.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(O)C1=CC2=CC(N(S(=O)(C(C=C3)=CC(Cl)=C3[N+]([O-])=O)=O)CC4=CC=C(C=C4)C5=CC=C(C=C5)OC)=CC=C2O1
• Molecular Weight: 593.00
• References & Citations: [1]Liang X, Zhao H, Du J, Li X, Li K, Zhao Z, Bi W, Zhang X, Yu D, Zhang J, Fang H, Hou X. Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy. Eur J Med Chem. 2023 Oct 5;258:115599.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported